The Psychedelic News Feed: April 1, 2024 – Psychedelic Alpha

PSYCHEDELIC DRUG DEVELOPMENT NEWS

Drug Developer Skips the Trip Entirely, Unveils Deuterium-Assisted Psychotherapy Candidate (Apr 1)

Initial reports describe the experience, though lacking psychedelics’ characteristic subjective effects, as “heavy” and “somewhat unstable”, but “noticeably patentable”.

Company Receives Notice of Allowance for U.S. Patent Covering Crystalline Polymorphs of Water (Apr 1)

The company announced the claims cover its lead candidate, Polymorph Eau.

AstraZeneca scores its second paediatric approval for Soliris in Japan – Pharmaceutical Technology

Soliris has previously been approved for use in paediatric and adult populations with paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS) in the

August 25, 2023

Nursa Secures $80M to Expand Healthcare Staffing Platform

What You Should Know: Nursa, a nationwide platform that exists to put a nurse at the bedside of every patient in need, today announced the completion

August 23, 2023

New study reveals brain clearance of toxins is reduced during sleep and anesthesia

The adipose-neural axis plays an important role in arrhythmogenesis.

May 15, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.